MedTrace Logo

Evaluation of a Patient-Reported Symptom Index for NMIBC

NCT03091764 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 498

Last updated 2021-10-13

No results posted yet for this study

Summary

This project will develop and evaluate a patient-reported symptom index to assess the impact of treatment for non-muscle invasive bladder cancer on patient burden, toxicity, symptoms and side effects. The symptom index will provide a method for assessing treatments from the patient's perspective; help healthcare professionals make better informed treatment decisions, and provide a method to be able to effectively evaluate treatments for non-muscle invasive bladder cancer.

Conditions

  • Superficial Bladder Cancer

Sponsors & Collaborators

  • Australian and New Zealand Urogenital and Prostate Cancer Trials Group

    collaborator OTHER

  • Cancer Australia

    collaborator OTHER

  • Cancer Council New South Wales

    collaborator OTHER

  • University of Sydney

    lead OTHER

Principal Investigators

  • Manish Patel, MBBS,PhD · University of Sydney

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-07-01
Primary Completion
2020-07-30
Completion
2021-08-30

Countries

  • United States
  • Australia
  • Canada
  • New Zealand
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03091764 on ClinicalTrials.gov